Experiment Overview
| Repository ID: | FR-FCM-Z74F | Experiment name: | Characterization of the effect of Ceralasertib and aPDL1 on CT26 tumours | MIFlowCyt score: | 82.00% |
| Primary researcher: | Adina Hughes | PI/manager: | Adina Hughes | Uploaded by: | Adina Hughes |
| Experiment dates: | 2021-06-11 - 2022-06-12 | Dataset uploaded: | Dec 2023 | Last updated: | Jan 2024 |
| Keywords: | [CyTOF] [PD-L1] [ATR] [checkpoint therapy] | Manuscripts: | |||
| Organizations: |
Astrazeneca, Early Oncology TDE, Cambridge, Cambridgeshire (United Kingdom)
|
||||
| Purpose: | The aim of the study is to evaluate the effect of an ATR inhibitor (Ceralasertib) dosed in combination with PD-L1 (checkpoint inhibitor) on the immune infiltrate in CT26 tumours | ||||
| Conclusion: | The ATR inhibitor Ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumour microenvironment | ||||
| Comments: | Tumours were established then treated for 14 days before being harvested. The single cell suspensions were stained across two 20-plex barcoded pools, using one cocktail and acquired over multiple days on CyTOF. Analysis of live Pt- CD45+CD3+ cells was conducted after spill matrix applied to files | ||||
| Funding: | Astrazeneca | ||||
| Quality control: | Live (Pt negative) single cell events analysed after debarcoding. Focused analysis on CD45+CD3+ for publication | ||||
Experiment variables
| Sample Type | |
|---|---|
| · CT26 mouse tumour | Compensated_TGp1ms1.fcs · Compensated_TGp1ms10.fcs · Compensated_TGp1ms11.fcs · Compensated_TGp1ms16.fcs · Compensated_TGp1ms5.fcs · Compensated_TGp1ms6.fcs · Compensated_TGp1ms7.fcs · Compensated_TGp1ms8.fcs · Compensated_TGp2ms21.fcs · Compensated_TGp2ms23.fcs · Compensated_TGp2ms31.fcs · Compensated_TGp2ms35.fcs · Compensated_TGp2ms38.fcs · Compensated_TGp2ms39.fcs · Compensated_TGp3ms42.fcs · Compensated_TGp3ms43.fcs · Compensated_TGp3ms44.fcs · Compensated_TGp3ms46.fcs · Compensated_TGp3ms48.fcs · Compensated_TGp3ms50.fcs · Compensated_TGp3ms51.fcs · Compensated_TGp3ms52.fcs · Compensated_TGp3ms53.fcs · Compensated_TGp3ms55.fcs · Compensated_TGp3ms58.fcs · Compensated_TGp3ms59.fcs · Compensated_TGp3ms60.fcs · Compensated_TGp4ms66.fcs · Compensated_TGp4ms67.fcs · Compensated_TGp4ms72.fcs · Compensated_TGp4ms73.fcs · Compensated_TGp4ms81.fcs · Compensated_TGp4ms82.fcs · Compensated_TGp4ms83.fcs · Compensated_TGp4ms84.fcs · Compensated_TGp4ms86.fcs · Compensated_TGp4ms87.fcs · Compensated_TGp4ms88.fcs · Compensated_TGp4ms89.fcs · Compensated_TGp4ms90.fcs |
| Doses | |
|---|---|
| · Vehicle 7days on 7 days off | Compensated_TGp1ms1.fcs · Compensated_TGp1ms10.fcs · Compensated_TGp1ms11.fcs · Compensated_TGp1ms16.fcs · Compensated_TGp1ms5.fcs · Compensated_TGp1ms6.fcs · Compensated_TGp1ms7.fcs · Compensated_TGp1ms8.fcs |
| · PD-L1 antibody 10mg/kg every 4th day for 14d | Compensated_TGp2ms21.fcs · Compensated_TGp2ms23.fcs · Compensated_TGp2ms31.fcs · Compensated_TGp2ms35.fcs · Compensated_TGp2ms38.fcs · Compensated_TGp2ms39.fcs |
| · AZD6738 25mg/kg BID 7days on 7 days off | Compensated_TGp3ms42.fcs · Compensated_TGp3ms43.fcs · Compensated_TGp3ms44.fcs · Compensated_TGp3ms46.fcs · Compensated_TGp3ms48.fcs · Compensated_TGp3ms50.fcs · Compensated_TGp3ms51.fcs · Compensated_TGp3ms52.fcs · Compensated_TGp3ms53.fcs · Compensated_TGp3ms55.fcs · Compensated_TGp3ms58.fcs · Compensated_TGp3ms59.fcs · Compensated_TGp3ms60.fcs |
| · AZD6738 25mg/kg BID 7days on 7 days off plus PD-L1 antibody 10mg/kg | Compensated_TGp4ms66.fcs · Compensated_TGp4ms67.fcs · Compensated_TGp4ms72.fcs · Compensated_TGp4ms73.fcs · Compensated_TGp4ms81.fcs · Compensated_TGp4ms82.fcs · Compensated_TGp4ms83.fcs · Compensated_TGp4ms84.fcs · Compensated_TGp4ms86.fcs · Compensated_TGp4ms87.fcs · Compensated_TGp4ms88.fcs · Compensated_TGp4ms89.fcs · Compensated_TGp4ms90.fcs |
| Timepoints | |
|---|---|
| · 14 days | Compensated_TGp1ms1.fcs · Compensated_TGp1ms10.fcs · Compensated_TGp1ms11.fcs · Compensated_TGp1ms16.fcs · Compensated_TGp1ms5.fcs · Compensated_TGp1ms6.fcs · Compensated_TGp1ms7.fcs · Compensated_TGp1ms8.fcs · Compensated_TGp2ms21.fcs · Compensated_TGp2ms23.fcs · Compensated_TGp2ms31.fcs · Compensated_TGp2ms35.fcs · Compensated_TGp2ms38.fcs · Compensated_TGp2ms39.fcs · Compensated_TGp3ms42.fcs · Compensated_TGp3ms43.fcs · Compensated_TGp3ms44.fcs · Compensated_TGp3ms46.fcs · Compensated_TGp3ms48.fcs · Compensated_TGp3ms50.fcs · Compensated_TGp3ms51.fcs · Compensated_TGp3ms52.fcs · Compensated_TGp3ms53.fcs · Compensated_TGp3ms55.fcs · Compensated_TGp3ms58.fcs · Compensated_TGp3ms59.fcs · Compensated_TGp3ms60.fcs · Compensated_TGp4ms66.fcs · Compensated_TGp4ms67.fcs · Compensated_TGp4ms72.fcs · Compensated_TGp4ms73.fcs · Compensated_TGp4ms81.fcs · Compensated_TGp4ms82.fcs · Compensated_TGp4ms83.fcs · Compensated_TGp4ms84.fcs · Compensated_TGp4ms86.fcs · Compensated_TGp4ms87.fcs · Compensated_TGp4ms88.fcs · Compensated_TGp4ms89.fcs · Compensated_TGp4ms90.fcs |
